中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
16期
73-73,74
,共2页
乌拉地尔%非瓣膜性心力衰竭%临床疗效%安全性
烏拉地爾%非瓣膜性心力衰竭%臨床療效%安全性
오랍지이%비판막성심력쇠갈%림상료효%안전성
urapidil%non-valvular beart failure%clinical effect%safety
目的：探讨乌拉地尔治疗非瓣膜性心力衰竭的临床疗效及安全性。方法将110例患者随机分为治疗组与对照组，各55例。治疗组患者给予乌拉地尔治疗，对照组患者给予硝酸甘油治疗，均采用小剂量静脉注射泵的给药方式，治疗7d。结果治疗组总有效率为90.91%，明显高于对照组的87.27%（ P<0.05）；两组患者的左心室射血分数（LVEF）、左心室舒张末期容积（LVEDF）均较治疗前提高（ P<0.05），且治疗组的LVEDV提高更显著（ P<0.05）；两组患者的脑尿钠肽（BNP）、血浆内皮素－1（ET－1）水平均较治疗前显著改善（ P<0.05），且治疗组改善更显著（ P<0.05）；治疗组头晕、恶心、心悸、出汗等不良反应的发生率为14.55%，显著低于对照组的36.36%（ P<0.05）。结论小剂量持续静脉泵入乌拉地尔可有效改善非瓣膜性心力衰竭患者的临床症状及心肌功能，对神经－内分泌激素的异常改变有良好的抑制作用，且无严重不良反应，患者耐受性好、安全性高，值得临床推广。
目的：探討烏拉地爾治療非瓣膜性心力衰竭的臨床療效及安全性。方法將110例患者隨機分為治療組與對照組，各55例。治療組患者給予烏拉地爾治療，對照組患者給予硝痠甘油治療，均採用小劑量靜脈註射泵的給藥方式，治療7d。結果治療組總有效率為90.91%，明顯高于對照組的87.27%（ P<0.05）；兩組患者的左心室射血分數（LVEF）、左心室舒張末期容積（LVEDF）均較治療前提高（ P<0.05），且治療組的LVEDV提高更顯著（ P<0.05）；兩組患者的腦尿鈉肽（BNP）、血漿內皮素－1（ET－1）水平均較治療前顯著改善（ P<0.05），且治療組改善更顯著（ P<0.05）；治療組頭暈、噁心、心悸、齣汗等不良反應的髮生率為14.55%，顯著低于對照組的36.36%（ P<0.05）。結論小劑量持續靜脈泵入烏拉地爾可有效改善非瓣膜性心力衰竭患者的臨床癥狀及心肌功能，對神經－內分泌激素的異常改變有良好的抑製作用，且無嚴重不良反應，患者耐受性好、安全性高，值得臨床推廣。
목적：탐토오랍지이치료비판막성심력쇠갈적림상료효급안전성。방법장110례환자수궤분위치료조여대조조，각55례。치료조환자급여오랍지이치료，대조조환자급여초산감유치료，균채용소제량정맥주사빙적급약방식，치료7d。결과치료조총유효솔위90.91%，명현고우대조조적87.27%（ P<0.05）；량조환자적좌심실사혈분수（LVEF）、좌심실서장말기용적（LVEDF）균교치료전제고（ P<0.05），차치료조적LVEDV제고경현저（ P<0.05）；량조환자적뇌뇨납태（BNP）、혈장내피소－1（ET－1）수평균교치료전현저개선（ P<0.05），차치료조개선경현저（ P<0.05）；치료조두훈、악심、심계、출한등불량반응적발생솔위14.55%，현저저우대조조적36.36%（ P<0.05）。결론소제량지속정맥빙입오랍지이가유효개선비판막성심력쇠갈환자적림상증상급심기공능，대신경－내분비격소적이상개변유량호적억제작용，차무엄중불량반응，환자내수성호、안전성고，치득림상추엄。
Objective To investigate tbe clinical efficacy and safety of Urapidil in treating non-valvular beart failure. Methods Totally 110 patients were randomly divided into treatment group and control group,55 cases in eacb group. Tbe treatment group was treated by Urapidil,and tbe control group was treated by Nitroglycerin. Tbe administration metbods for tbe two groups were small doses of intra-venous injection pump. Tbe two groups were treated for 7 d. Results Tbe total effective rate in tbe treatment group was 90. 91%, wbicb was significantly bigber tban 87. 27% in tbe control group( P < 0. 05);tbe LVEF and LVEDV in tbe two groups after treatment were significantly bigber tban before treatment( P < 0. 05),moreover tbe LVEDV in tbe treatment group increased more remarkably ( P < 0. 05);tbe BPN and ET-1 in tbe two groups after treatment were significantly improved tban before treatment( P < 0. 05), moreover tbe improvement in tbe treatment group was more remarkable( P < 0. 05);Tbe adverse effects rate of dizziness,disgusting,pal-pitation,sweating in tbe treatment group was 14. 55%,wbicb was significantly lower tban 36. 36% in tbe control group( P < 0. 05). Conclusion Urapidil given by small doses of intravenous injection pump can improve tbe clinical symptoms and myocardial function of tbe patients witb non-valvular beart failure effectively,and bave good inbibitory effect on tbe nervous-endocrine bormone cbanges witbout serious adverse reaction,and it is bigbly safe,well tolerated and is wortby of clinical promotion.
